Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Yet one of the company's most promising candidates, weight management medicine MariTide, failed to produce the kinds of results the market wanted in a phase 2 clinical trial, and the stock fell. Even ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...